In a report released yesterday, Jason Zemansky from Bank of America Securities reiterated a Sell rating on Madrigal Pharmaceuticals, with a price target of $266.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jason Zemansky has given his Sell rating due to a combination of factors, primarily centered around the current valuation of Madrigal Pharmaceuticals’ stock and the competitive landscape. Despite Madrigal’s impressive sales growth and the successful launch of Rezdiffra, Zemansky believes that the stock’s current price already reflects these achievements, leaving limited room for further upside.
Additionally, Zemansky expresses concerns about the potential risks posed by upcoming competitors, such as the GLP-1s expected to launch soon, and the longer-term threats from FGF21s. He also highlights uncertainties related to payer management and the impact of semaglutide, which could affect Madrigal’s market position. While acknowledging Madrigal’s efforts to address these challenges, Zemansky remains cautious about the stock’s future performance, leading to his Sell recommendation.
According to TipRanks, Zemansky is a 4-star analyst with an average return of 8.8% and a 55.35% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Madrigal Pharmaceuticals, and Kura Oncology.